Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

Wilson, Timothy R., Lee, Diana Y., Berry, Leanne, Shames, David S., Settleman, Jeff·2011·Cancer Cell
DOI 10.1016/j.ccr.2011.07.011

Cited by (161)

Items 101–161 of 161

  1. Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
    Kimio Yonesaka, Naoki Takegawa, Taroh Satoh, Hiroto Ueda, Takeshi Yoshida, Masayuki Takeda, Toshio Shimizu, Yasutaka Chiba, Isamu Okamoto, Kazuto Nishio et al. · 2015 · PLoS ONE
  2. Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer
    Cathy Beatrice Moelans, Caroline M. G. van Maldegem, Elsken van der Wall, P. J. van Diest · 2018 · Oncotarget
  3. Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions
    Kalyani Bindu Karunakaran, Naveena V. K. Yanamala, Gregory Boyce, Michael J. Becich, Madhavi K. Ganapathiraju · 2021 · Cancers
  4. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells
    Jinkyoung Kim, Jiyun Lee, Chungyeul Kim, Jin‐Hyuk Choi, Aeree Kim · 2015 · Tumor Biology
  5. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
    Christophe Le Clorennec, Hervé Bazin, Olivier Dubreuil, Christel Larbouret, Charline Ogier, Yassamine Lazrek, Véronique Garambois, Marie‐Alix Poul, Philippe Mondon, Jean-Marc M. Barret et al. · 2017 · Molecular Cancer Therapeutics
  6. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma
    Marta Baro, Cecilia López Sambrooks, Barbara Ann Burtness, Mark A. Lemmon, Joseph N. Contessa · 2019 · Molecular Cancer Therapeutics
  7. DRIM: A Web-Based System for Investigating Drug Response at the Molecular Level by Condition-Specific Multi-Omics Data Integration
    Minsik Oh, Sungjoon Park, Sangseon Lee, Dohoon Lee, Sangsoo Lim, Dabin Jeong, Kyuri Jo, Inuk Jung, Sun Kim · 2020 · Frontiers in Genetics
  8. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition
    Roberta L. Beauchamp, Serkan Erdin, Luke Witt, Justin T. Jordan, Scott Randall Plotkin, James F. Gusella, Vijaya Ramesh · 2020 · Journal of Biological Chemistry
  9. Nucleolar localization of the ErbB3 receptor as a new target in glioblastoma
    Marzia Tagliaferro, Paolo Rosa, Gian Carlo Bellenchi, Daniela Bastianelli, Rosa Trotta, Claudia Tito, Francesco Fazi, Antonella Calogero, Donatella Ponti · 2022 · BMC Molecular and Cell Biology
  10. The Minority Report: Targeting the Rare Oncogenes in NSCLC
    Caroline Elizabeth McCoach, Robert Charles Doebele · 2014 · Current Treatment Options in Oncology
  11. LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
    Shunji Takahashi, Takayuki Kobayashi, Junichi Tomomatsu, Yoshinori Ito, Hisanobu Oda, Tatsuhiro Kajitani, Tomoyuki Kakizume, Takeshi Tajima, Hiromi Takeuchi, Heiko Maacke et al. · 2016 · Cancer Chemotherapy and Pharmacology
  12. HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance
    Nicoleta Sinevici, Bahar Ataeinia, Veronica Zehnder, Kevin Lin, Lauren Grove, Pedram Heidari, Umar Mahmood · 2020 · Frontiers in Oncology
  13. Global signal peptide profiling reveals principles of selective Sec61 inhibition
    Nicole A. Wenzell, Brian Benjamin Tuch, Dustin L. McMinn, Matthew Lyons, Christopher J. Kirk, Jack Taunton · 2024 · Nature Chemical Biology
  14. Targeting the Human Epidermal Growth Factor Receptor 2 Pathway in Breast Cancer
    Senthilkumar Damodaran, Erin Macrae Olson · 2012 · Hospital Practice
  15. Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
    Mark M. Moasser · 2022 · Cancer Research
  16. Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas
    Bénédicte Rysman, F. Mouawad, Abigaëlle Gros, Amélie Lansiaux, Dominique Chevalier, Samuel Meignan · 2016 · Head & Neck
  17. siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells
    Heng-heng Yuan, Yingnan Yang, Jian-Hua Zhou, Yanjing Li, Liying Wang, Junwei Qin, Tao Liu, Zhenzhen Li, Qingxin Zhou, Xiao-Li Wei et al. · 2017 · Oncotarget
  18. The impact of structural biology in medicine illustrated with four case studies
    Tiancen Hu, Elizabeth R. Sprague, Michelle Fodor, Travis Stams, Kirk Clark, Sandra W. Cowan‐Jacob · 2017 · Journal of Molecular Medicine
  19. HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive
    Marcia R. Campbell, Mark M. Moasser · 2015 · Clinical Cancer Research
  20. SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs
    Wenjing Li, Chengying Xie, Xi Zhu, Jiao Tang, Lei Wang, Liguang Lou · 2024 · Acta Pharmacologica Sinica
  21. Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
    Corina Buta, Eva Benabou, Marie Lequoy, Hélène Regnault, Dominique Wendum, Fatiha Merabtene, Hamza Chettouh, Lynda Aoudjehane, Filoména Conti, Yves Chrétien et al. · 2016 · Journal of Experimental & Clinical Cancer Research
  22. Inflammasome Inhibition Suppresses Alveolar Cell Permeability Through Retention of Neuregulin-1 (NRG-1)
    Venugopal Rajanbabu, Lakshmi Galam, Ruan Cox, Jutaro Fukumoto, Young Susan Cho, Prasanna Tamarapu Parthasarathy, Richard F. Lockey, Narasaiah Kolliputi · 2015 · Cellular Physiology and Biochemistry
  23. Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
    Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Gabriel Jiménez-Domínguez, Sylvie Choblet, Emmanuelle Liaudet‐Coopman, Martine Cérutti et al. · 2023 · Frontiers in Immunology
  24. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response
    Jacob P. Turowec, Esther W.T. Lau, Xiaowei Wang, Kevin R. Brown, Frédéric A. Fellouse, Kamaldeep K. Jawanda, James Pan, Jason Moffat, Sachdev S. Sidhu · 2018 · Journal of Biological Chemistry
  25. Clinical Trial Outcomes
    Robin Martinez · 2019 · JACC Heart Failure
  26. Rationale for Targeting the ErbB Family of Receptors in Patients with Advanced Squamous Cell Carcinoma of the Lung
    Peter Edward Hall, James F. Spicer, Sanjay Popat · 2015 · Future Oncology
  27. Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer: Her1–4 and c-Met in Conjunction with the Clinical Features and Human Papillomavirus (p16) Status
    Eric Deuß, Dorothee Gößwein, Désirée Gül, S. Zimmer, Sebastian Foersch, Claudia S. Eger, Ivonne Limburg, Roland H. Stauber, Julian Künzel · 2020 · Cancers
  28. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells
    Smita Awasthi, Heather J. Ezelle, Bret A. Hassel, Anne W. Hamburger · 2015 · Molecular and Cellular Biochemistry
  29. CAN017, a novel anti-HER3 antibody, exerted great potency in mouse avatars of esophageal squamous cell carcinoma with NRG1 as a biomarker.
    Haiyan Liao, Cheng Zhang, Zuhua Chen, Ya Gao, Zhongwu Li, Lingyu Wang, Yanyan Li, Lin Shen, Jing Gao · 2021 · PubMed Central
  30. Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
    Srikumar Chakravarthi, Barani Karikalan · 2020 · Current Cancer Therapy Reviews
  31. Expression and Localization of Neuregulin-1 (Nrg1) and ErbB2/ErbB4 Receptors
    Weijiang Zhao · 2013 · Intern J Endocrinol Metab
  32. New driver alterations in non-small cell lung cancer: a narrative review
    Marco Filetti, Alessandro Rossi, Beatrice Taurelli Salimbeni, Marta Piras, Evelina Rogges, Arianna Di Napoli, Paolo Marchetti, Raffaele Giusti · 2021 · Precision Cancer Medicine
  33. A prognostic biomarker NRG1 promotes U‑87 MG glioblastoma cell malignancy by inhibiting autophagy via ERBB2/AKT/mTOR pathway
    Jia‐zhe Lin, Nuan Lin, Weijiang Zhao · 2023 · Journal of Cellular Biochemistry
  34. EGFR Inhibitors as Therapeutic Agents in Head and Neck Cancer
    Hanqing Liu, Jennifer R. Cracchiolo, Tim N. Beck, Ilya G. Serebriiskii, Erica A. Golemis · 2014 · Springer eBooks
  35. Mesothelioma Interactome with 367 Novel Protein-Protein Interactions
    Kalyani Bindu Karunakaran, Naveena V. K. Yanamala, Gregory Boyce, Madhavi K. Ganapathiraju · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  36. NOTCH1 signaling promotes protein stability of HER3 through the AKT pathway in squamous cell carcinoma of head and neck
    Yi‐Ping Wang, I-Ju Liu, Kai-Chi Chen, Han‐Chung Wu · 2021 · Oncogenesis
  37. Important Early Advances in Squamous Cell Carcinoma of the Head and Neck
    Éric Bissada, Irene Braña, Lillian L. Siu · 2012 · American Society of Clinical Oncology Educational Book
  38. CD98 regulates the phosphorylation of HER2 and a bispecific anti‐HER2 / CD98 antibody inhibits the growth signal of human breast cancer cells
    Akitaka Yamasaki, Kumiko Maruyama‐Takahashi, Kento Nishida, Shogo Okazaki, Kouki Okita, Yasutoshi Akiyama, Hideaki Suzuki, Yuichi Endo, Kazue Masuko, Takashi Masuko et al. · 2023 · Genes to Cells
  39. Le récepteur HER3 ou ERBB3
    Christel Larbouret, Nadège Gaborit, Marie‐Alix Poul, André Pèlegrin, Thierry Chardès · 2015 · médecine/sciences
  40. EGFR Targeted Inhibition Resistance
    Demirkan Besim Gursel, Cody D. Schlaff, John Andrew Boockvar · 2012 · Neurosurgery
  41. HER2-Pozitif Meme Kanseri Hastalarında Rac1 Ekspresyonunun Trastuzumab Direnci İle İlişkisi
    Umut Varol · 2013 · International Journal of Hematology and Oncology
  42. Blockage of EGFR Pathway for Anticancer Therapy in Squamous Cell Carcinoma of the Head and Neck
    Sandra Schmitz, Jean‐Pascal Machiels · 2017 · Springer eBooks
  43. HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
    Edward L. Nelson · 2014 · Clinical Investigation
  44. Targeting the ErbB Family in Head and Neck Cancer
    Anna A. Kiseleva, Tim N. Beck, Ilya G. Serebriiskii, Hanqing Liu, Barbara Ann Burtness, Erica A. Golemis · 2018 · Current cancer research
  45. Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbations
    Marc Creixell, Scott D. Taylor, Jacqueline S. Gerritsen, Song Yi Bae, Mingxuan Jiang, Teresa Augustin, Michelle Loui, Carmen Boixo, Pau Creixell, Forest M. White et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  46. Discovery of Predictive Biomarkers for Anticancer Drugs
    Richard M. Neve, Lisa D. Belmont, Richard Bourgon, Marie Evangelista, Xiaodong Huang, Maike Schmidt, Robert L. Yauch, Jeffrey E. Settleman · 2013 · Methods and principles in medicinal chemistry
  47. Dietary- and fasting-based interventions as novel approaches to improve the efficacy of cancer treatment
    Sebastian Brandhorst · 2013 · DuEPublico (University of Duisburg-Essen)
  48. Association of Rac1 Expression with Trastuzumab Resistance in HER2-Positive Breast Cancer
    Umut Varol, Burçak Karaca, Püsem Patır, Alper Şener, Osman Zekioğlu, A. Tulga Ulus, Rüçhan Uslu · 2013
  49. and HER3 in hepatocellular carcinoma: status and regulation by insulin
    Corina Buta, Eva Benabou, Marie Lequoy, Dominique Wendum, Hamza Chettouh, Lynda Aoudjehane, Filoména Conti, Yves Chrétien · 2016
  50. [Assessment of the effectiveness of Androcur in the treatment of precocious puberty].
    Semicheva Tv · 1989 · PubMed
  51. Investigations into how best to target FGFR2 mutant endometrial cancer
    Xinyan Geng · 2017 · Queensland University of Technology
  52. Anticuerpos conjugados a fármacos frente a receptores ERBB: nuevas indicaciones y mecanismos de resistencia
    Sara García Alonso · 2018 · Gredos (University of Salamanca)
  53. Epidermal growth factor-like ligands regulate dimer selection.
    Jamie S. Rush · 2018
  54. Faculty Opinions recommendation of Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
    Charlotte Lynne Bevan, Theodora A. Constantin · 2021 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  55. Beyond the bullseye
    2011 · Nature
  56. Supplementary Materials and Methods from Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
    Takashi Nakaoku, Koji Tsuta, Hitoshi Ichikawa, Kouya Shiraishi, Hiromi Sakamoto, Masato Enari, Koh Furuta, Yoko Shimada, Hideaki Ogiwara, Shun-ichi I. WATANABE et al. · 2023
  57. Supplementary Materials and Methods from Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
    Takashi Nakaoku, Koji Tsuta, Hitoshi Ichikawa, Kouya Shiraishi, Hiromi Sakamoto, Masato Enari, Koh Furuta, Yoko Shimada, Hideaki Ogiwara, Shun-ichi I. WATANABE et al. · 2023
  58. Additional file 3 of NRG1 fusions in breast cancer
    Karen Howarth, Tashfina Mirza, Cooke, Susanna L., Chin, Suet-Feung, Jessica C. M. Pole, Ernest Turro, Matthew Eldridge, Garcia, Raquel Manzano, Oscar M. Rueda, Boursnell, Chris et al. · 2021 · Figshare
  59. Additional file 1 of NRG1 fusions in breast cancer
    Karen Howarth, Tashfina Mirza, Cooke, Susanna L., Chin, Suet-Feung, Jessica C. M. Pole, Ernest Turro, Matthew Eldridge, Garcia, Raquel Manzano, Oscar M. Rueda, Boursnell, Chris et al. · 2021 · Figshare
  60. Nouvelle perspective thérapeutique pour le cancer du pancréas : ciblage des ligands des récepteurs de la famille HER exprimés par la tumeur et son microenvironnement
    Charline Ogier · 2017 · theses.fr (ABES)
  61. AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer
    Marc Creixell, Scott D. Taylor, Jacqueline S. Gerritsen, Mingxuan Jiang, Song Yi Bae, Teresa Augustin, Michelle Loui, Carmen Boixo, Saki Minamino, Victoria Gong et al. · 2026 · Cell Reports